2. Search Result
Search Result
Results for "

JQ1

" in MedChemExpress (MCE) Product Catalog:

75

Inhibitors & Agonists

2

Fluorescent Dyes

4

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13030
    (+)-JQ-1
    Maximum Cited Publications
    295 Publications Verification

    JQ1

    		 Epigenetic Reader Domain Autophagy Ligands for Target Protein for PROTAC Neurological Disease Cancer
    (+)-JQ-1 (JQ1), a chemical probe, is a potent, specific, CNS-penetrant and reversible BET bromodomain inhibitor, with IC50s of 77 and 33 nM for the first and second bromodomain (BRD4(1/2)) [1]. (+)-JQ-1 also activates autophagy .
    (+)-JQ-1
  • HY-78695
    JQ-1 carboxylic acid
    5+ Cited Publications

    		 Epigenetic Reader Domain PD-1/PD-L1 Ligands for Target Protein for PROTAC Cancer
    JQ-1 carboxylic acid, a (+)-JQ-1 (HY-13030) derivative, is a potent BET bromodomain inhibitor. JQ-1 carboxylic acid can be used to synthesize PROTAC, which can target the degradation of BRD4.
    JQ-1 carboxylic acid
  • HY-112789
    (+)-JQ1 PA
    1 Publications Verification

    		 Epigenetic Reader Domain Cancer
    (+)-JQ1 PA is a derivative of the Bromodomain and extra-terminal (BET) inhibitor JQ1, with an IC50 of 10.4 nM. (+)-JQ1 PA is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    (+)-JQ1 PA
  • HY-101838
    dBET1
    15+ Cited Publications

    		 PROTACs Epigenetic Reader Domain Cancer
    dBET1 is a PROTAC connected by ligands for Cereblon and BRD4 with an EC50 of 430 nM. dBET1 is a PROTAC that composes of (+)-JQ1 (HY-13030) linked to NSC 527179 (HY-14658) with a linker [1].
    dBET1
  • HY-13030A
    (R)-(-)-JQ1 Enantiomer
    5+ Cited Publications

    		 Epigenetic Reader Domain Cancer
    (R)-(-)-JQ1 Enantiomer is the stereoisomer of (+)-JQ1. (+)-JQ1 potently decreases expression of both BRD4 target genes, whereas (R)-(-)-JQ1 Enantiomer has no effect.
    (R)-(-)-JQ1 Enantiomer
  • HY-145667
    Biotinylated-JQ1
    1 Publications Verification

    Biotin-JQ1

    		 Epigenetic Reader Domain Cancer
    Biotinylated-JQ1 (Biotin-JQ1) is a biotinylated derivative of JQ1 with high affinity for the bromodomain of BRD4. Biotinylated-JQ1 inhibits MM1.S multiple myeloma cells proliferation with the EC50 of 0.4 μM [1].
    Biotinylated-JQ1
  • HY-156214
    NICE-01

    AP1867-PEG2-JQ1; AP-PEG2-JQ1

    		 Epigenetic Reader Domain Others
    NICE-01 (AP1867-PEG2-JQ1; AP-PEG2-JQ1) is a bifunctional compound that bind to proteins in separate cellular compartments that can induce nuclear import of cytosolic cargoes, using nuclear-localized bromodomain-containing protein 4 (BRD4) as a “carrier” for co-import and nuclear trapping of cytosolic proteins [1].
    NICE-01
  • HY-W007545
    NH2-PEG3

    PROTAC Linker 35

    		 PROTAC Linkers Cancer
    NH2-PEG3 (PROTAC Linker 35) is a PROTAC linker, which belongs to a polyethylene glycol (PEG) linker. NH2-PEG3 (PROTAC Linker 35) can be used in the synthesis of the PROTAC (β-NF-JQ1) [1].
    NH2-PEG3
  • HY-114407
    TD-428

    		PROTACs Epigenetic Reader Domain Cancer
    TD-428 is a PROTAC connected by ligands for Cereblon and BRD4. TD-428 is a highly specific BRD4 degrader with a DC50 of 0.32 nM [1]. TD-428 is a BET PROTAC, which comprises TD-106 (a CRBN ligand) linked to JQ1 (a BET inhibitor). TD-428 efficiently induce BET protein degradation [1].
    TD-428
  • HY-129917
    KB02-JQ1
    4 Publications Verification

    		 PROTACs Epigenetic Reader Domain Cancer
    KB02-JQ1 is a highly selective and PROTAC-based BRD4 degrader (molecular glue), but does not degrade BRD2 or BRD3. KB02-JQ1 promotes BRD4 degradation by covalently modifying DCAF16 (E3 ligase) and can improve the durability of protein degradation in biological systems. JQ1 binds ubiquitin E3 ligase ligand KB02 via a linker to form KB02-JQ1 [1].
    KB02-JQ1
  • HY-111875
    SNIPER(BRD)-1

    		SNIPERs PROTACs Epigenetic Reader Domain Cancer
    SNIPER(BRD)-1 is a SNIPER degrader of BRD4, cIAP1 and XIAP. SNIPER(BRD)-1 has IC50 values of 6.8 nM, 17 nM and 49 nM for cIAP1, cIAP2 and XIAP, respectively. SNIPER(BRD)-1 can be used for cancer research [1]. (Blue: LCL161 (HY-15518); Black: linker (HY-W008005); Pink: (+)-JQ-1 (HY-13030))
    SNIPER(BRD)-1
  • HY-174995
    JQ-1-Azidopropylamine

    		Target Protein Ligand-Linker Conjugates Epigenetic Reader Domain Cancer
    JQ-1-Azidopropylamine is an Target Protein Ligand-Linker Conjugate that incorporates a ligand for BRD4 (HY-78695) and a PROTAC linker (HY-151862), which recruits E3 ligases. JQ-1-Azidopropylamine can be used for synthesis of PROTAC JY-21 (HY-174975) [1].
    JQ-1-Azidopropylamine
  • HY-148864
    JQ1-TCO

    		Epigenetic Reader Domain Cancer
    JQ1-TCO is the double bond E configuration of JQ1-TCO (HY-148864A). JQ1-TCO is a derivative of JQ1 (HY-13030), an inhibitor of BET. JQ1-TCO is suitable for click chemistry and can be used as molecular probes in vitro and in vivo [1] .
    JQ1-TCO
  • HY-147046
    ET-JQ1-OH

    		Epigenetic Reader Domain Ligands for Target Protein for PROTAC Cancer
    ET-JQ1-OH is an allele-specific BET inhibitor. ET-JQ1-OH can serve as a Ligand for Target Protein for PROTAC, and is used for the development and design of PROTAC Brd4 degraders, such as AB3145 (HY-180923).
    ET-JQ1-OH
  • HY-131385
    KB02-COOH

    		Ligands for E3 Ligase Cancer
    KB02-COOH is a fragment of synthesis of ubiquitin E3 ligase ligand KB02. KB02 can be used in the synthesis of PROTAC, such as KB02-JQ1 (HY-129917) and KB02-SLF (HY-129610) [1].
    KB02-COOH
  • HY-130256
    β-NF-JQ1

    		PROTACs Epigenetic Reader Domain Cancer
    β-NF-JQ1 is a PROTAC that recruits Aryl Hydrocarbon Receptor E3 ligase to target proteins. β-NF-JQ1 is directed against bromodomain-containing (BRD) proteins using β-NF as an AhR ligand, induces the interaction of AhR and BRD proteins, and displays effective anticancer activity that correlated with protein knockdown activity [1].
    β-NF-JQ1
  • HY-169150
    JQ-1 carboxylic acid-PEG3-C2-NH2

    		E3 Ligase Ligand-Linker Conjugates Cancer
    JQ-1 carboxylic acid-PEG3-C2-NH2 is a E3 ligase ligand-linker conjugate that can be used in the synthesis of PROTACT [1].
    JQ-1 carboxylic acid-PEG3-C2-NH2
  • HY-153385
    TMX1

    		Molecular Glues Epigenetic Reader Domain Cancer
    TMX1 is a covalent, selective BRD4 molecular glue degrader. TMX1 binds to the JQ1-binding site of BRD4BD2, forms covalent bonds with Cys58 of DCAF16 and Cys87 of GAK in a BRD4BD2-dependent template-assisted manner, stabilizes the BRD4-TMX1-DCAF16 ternary complex, and promotes the ubiquitination of BRD4 via the CRL4DCAF16 ubiquitin ligase complex. TMX1 induces selective degradation of BRD4, mild degradation of BRD2 and BRD3, as well as DCAF16-dependent cytotoxicity [1] .
    TMX1
  • HY-148864A
    (Z)-JQ1-TCO

    JQ1-CCO

    		 Epigenetic Reader Domain Cancer
    (Z)-JQ1-TCO is a derivative of JQ1 (HY-13030), an inhibitor of BET. (Z)-JQ1-TCO is suitable for click chemistry and can be used as molecular probes in vitro and in vivo [1] .
    (Z)-JQ1-TCO
  • HY-111976
    MT1

    		Epigenetic Reader Domain Cancer
    MT1 is a bivalent chemical probe of BET bromodomains, with an IC50 of 0.789 nM for BRD4(1) [1].
    MT1
  • HY-158764
    PROTAC BET Degrader-12

    		PROTACs Epigenetic Reader Domain Cancer
    PROTAC BET Degrader-12 (Compound 8b) is a PROTAC degrader for bromodomain and extra-terminal domain (BET)-containing proteins, which degrades the BRD3 and BRD4 in a DCAF11-dependent manner. PROTAC BET Degrader-12 inhibits cell viability of KBM7 with a DC50 of 305.2 nM. (Pink: ligand for target protein (+)-JQ-1 (HY-13030); Black: linker (HY-159077); Blue: ligand for E3 ligase (HY-159076)) [1]
    PROTAC BET Degrader-12
  • HY-168936
    DP-15

    		PROTACs Epigenetic Reader Domain Apoptosis Cancer
    DP-15 is the degrader for GSPT1 and BRD4 with DC50s of 5.25 nM and 0.48 nM. DP-15 exhibits anti-proliferative activity of AML cells and NHL cells with an IC50 of nanomolar levels, arrests the cell cycle at G1 phase, and induces apoptosis in MOLM13. DP-15 exhibits anti-leukemia activity in MOLM-13 xenograft mouse models [1]. (Pink: ligand for target protein JQ-1 carboxylic acid (HY-78695); Black: linker (HY-W262798); Blue: ligand for E3 ligase Cereblon Thalidomide-5-OH (HY-23095))
    DP-15
  • HY-169369
    TRAP-1

    XJZ-06-462

    		 MDM-2/p53 Apoptosis Cancer
    TRAP-1 (XJZ-06-462) is a non-covalent regulated induced proximity targeting chimera (RIPTAC) with JQ-1 carboxylic acid (HY-78695) as its target protein ligand. TRAP-1 forms a ternary complex with p53 Y220C and BRD4, potently activates p53 transcription, and inhibits the growth and proliferation of tumor cells. TRAP-1 upregulates p21 and other p53 target genes in pancreatic cell lines carrying p53 Y220C, and induces cellular senescence and apoptosis. TRAP-1 can be used in cancer research involving p53 Y220C-carrying tumors [1].
    TRAP-1
  • HY-101460
    Tz-Thalidomide

    		E3 Ligase Ligand-Linker Conjugates Drug Derivative Cancer
    Tz-Thalidomide is a tetrazine-tagged Thalidomide (HY-14658), an E3 ligase ligand. Tz-Thalidomide self-assembles with TCO-labeled target protein inhibitors, forming a CLIP-TAC (targeted protein degradation chimera) via click chemistry. This chimera recruits the E3 ubiquitin ligase CRBN to the target protein, thereby inducing ubiquitination and subsequent degradation of the target protein. When used in combination with JQ1-TCO (HY-148864), Tz-Thalidomide induces concentration-dependent degradation of BRD4 in cells. When combined with ERK-targeting protein inhibitors, Tz-Thalidomide induces degradation of ERK1/2 in cells. Tz-Thalidomide can be used in cancer-related research [1].
    Tz-Thalidomide
  • HY-176391
    Ad-JQ1

    		Target Protein Ligand-Linker Conjugates Epigenetic Reader Domain Cancer
    Ad-JQ1 (Compound 16) is an Target Protein Ligand-Linker Conjugate that incorporates a ligand for BRD4 (HY-78695) and a PROTAC linker (HY-176390), which recruits E3 ligases. Ad-JQ1 can be used for synthesis of PROTAC β-NF-JQ1 (HY-130256) [1].
    Ad-JQ1
  • HY-100696
    PNZ5

    		Epigenetic Reader Domain Cancer
    PNZ5 is a potent and isoxazole-based pan-BET inhibitor with high selectivity and potency similar to the well-established (+)-JQ1, with a KD of 5.43 nM for BRD4(1) [1].
    PNZ5
  • HY-137075
    (±)-JQ1

    		Epigenetic Reader Domain Cancer
    (±)-JQ1 is the racemate of (+)-JQ-1 (HY-13030) [1].
    (±)-JQ1
  • HY-156774
    CCW 28-3

    		PROTACs Epigenetic Reader Domain Others
    CCW 28-3 is a PROTAC-based BRD4 degrader in a proteasome- and RNF4-dependent manner (Pink: JQ-1 (carboxylic acid) (HY-78695); Black: linker (HY-170384); Blue: RNF4 ligand CCW16 (HY-143346)) [1].
    CCW 28-3
  • HY-169358
    L134

    		PROTACs Epigenetic Reader Domain Cancer
    L134 is a potent PROTAC BRD4 degrader with a DC50 value of 7.36 nM. L134 mediates the degradation of BRD4 via the ubiquitin-proteasome system in a DCAF11-dependent manner (Blue: JQ-1 (carboxylic acid) (HY-78695), Black: linker (HY-W004640); Pink: E3 ligase ligand, L321 (HY-169359)) [1].
    L134
  • HY-169150A
    JQ-1 carboxylic acid-PEG3-C2-NH2 hydrochloride

    		E3 Ligase Ligand-Linker Conjugates Cancer
    JQ-1 carboxylic acid-PEG3-C2-NH2 (hydrochloride) is a E3 ligase ligand-linker conjugate that can be used in the synthesis of PROTACT [1].
    JQ-1 carboxylic acid-PEG3-C2-NH2 hydrochloride
  • HY-132991
    ML 2-14
    1 Publications Verification

    		 PROTACs Epigenetic Reader Domain Cancer
    ML 2-14 is a PROTAC targeting BRD4 with a C4 alkyl linker. ML 2-14 consists of the E3 ligase ligand EN219 (HY-115715) (bule part), the target protein ligand JQ-1 (HY-13030) (red part), and the PROTAC linker (balck part). ML 2-14 can effectively degrade BRD4 in 231MFP breast cancer cells, and this effect can be reversed by the proteasome inhibitor Bortezomib (HY-10227) and the E1 activase inhibitor TAK-243 (HY-100487) [1].
    ML 2-14
  • HY-161125
    (+)-JQ1-OH

    		Drug Metabolite Others
    (+)-JQ1-OH is the major metabolite of (+)-JQ1(HY-13030). (+)-JQ-1 (JQ1) is a potent, specific, and reversible BET bromodomain inhibitor, with IC50s of 77 and 33 nM for the first and second bromodomain (BRD4(1/2)). (+)-JQ-1 also activates autophagy [1].
    (+)-JQ1-OH
  • HY-111823
    VH032 thiol

    VHL ligand 6

    		 Ligands for E3 Ligase Cancer
    VH032 thiol (VHL ligand 6) is a VHL ligand, which binds to pan-BET inhibitor JQ1 via a linker to form PROTAC [1].
    VH032 thiol
  • HY-131633A
    (+)-JQ-1-aldehyde

    		Epigenetic Reader Domain Cancer
    (+)-JQ-1-aldehyde is the aldehyde form of (+)-JQ1. (+)-JQ-1-aldehyde can be uesd as a precursor to synthesize PROTACs, which targets BET bromodomains [1].
    (+)-JQ-1-aldehyde
  • HY-169082
    JQ-1 (carboxylic acid)-NH-C2-NH-COOH

    		E3 Ligase Ligand-Linker Conjugates Cancer
    JQ-1 (carboxylic acid)-NH-C2-NH-COOH is a conjugate of E3 ligase ligand and linker (E3 Ligase Ligand-Linker Conjugates), which is composed of JQ-1 carboxylic acid (HY-78695) and the corresponding linker: (2-Aminoethyl)carbamic acid (HY-W398806). JQ-1 (carboxylic acid)-NH-C2-NH-COOH can be used as a Cereblon ligand to recruit CRBN protein and as a key intermediate for the synthesis of complete PROTACs molecules [1].
    JQ-1 (carboxylic acid)-NH-C2-NH-COOH
  • HY-178510
    JQ1-S(GlcNAc)Cq

    		PROTACs Epigenetic Reader Domain Cancer
    JQ1-S(GlcNAc)Cq is a sugar-coated BRD4 PROTAC degrader. JQ1-S(GlcNAc)Cq can inhibit the formation of the ternary complex between CRBN and BRD4(BD1/BD2). JQ1-S(GlcNAc)Cq can be used for the research of cancer [1]. (Structure Note: Pink: BRD4 ligand (HY-78695); Blue: CRBN ligand (HY-178514); Black: linker (HY-W105727); BRD4 ligand-Linker: (HY-178519))
    JQ1-S(GlcNAc)Cq
  • HY-172126
    JQ-1 (carboxylic acid)-NH-C2-NH-AMPRO-222

    		Target Protein Ligand-Linker Conjugates Epigenetic Reader Domain Cancer
    JQ-1 (carboxylic acid)-NH-C2-NH-AMPRO-222 incorporates a ligand for BRD4, and a PROTACs linker that can be used in the synthesis of PROTAC BRD4 Degrader-29 (HY-172124) [1].
    JQ-1 (carboxylic acid)-NH-C2-NH-AMPRO-222
  • HY-170900
    SJ44236

    		PROTACs Epigenetic Reader Domain Cancer
    SJ44236 is the PROTAC degrader for BET that degrades BRD2 (DC50 = 0.127 nM), BRD3 and BRD4. SJ44236 exhibits cytotoxicity in cell MV4-11 and HD-MB03 with IC50s of 0.12 nM and 0.92 nM. SJ44236 downregulates the expression of c-Myc, upregulates the expression of p53. SJ44236 exhibits a good orally bioavailability of 45% in mice [1]. (Pink: ligand for target protein JQ-1 carboxylic acid (HY-78695); Black: linker (HY-W012935); Blue: ligand for E3 ligase Cereblon E3 ligase Ligand 54 (HY-W890189))
    SJ44236
  • HY-181847
    JQ-1 (carboxylic acid)-NHS

    		Drug Derivative Others
    JQ-1 (carboxylic acid)-NHS is an ester derivative of (+)-JQ-1 (HY-13030). JQ-1 (carboxylic acid)-NHS serves as a negative control [1].
    JQ-1 (carboxylic acid)-NHS
  • HY-178519
    JQ-1 (carboxylic acid)-NH-C8-COOH

    		Target Protein Ligand-Linker Conjugates Cancer
    JQ-1 (carboxylic acid)-NH-C8-COOH is a synthetic target protein ligand-conjugate linker, which can be used to synthesize JQ1-S(GlcNAc)Cq (HY-178510). JQ1-S(GlcNAc)Cq is a potent Sugar-Coated PROTAC bifunctional degrader with anti-tumor activity [1].
    JQ-1 (carboxylic acid)-NH-C8-COOH
  • HY-176724
    ZnPc-O3-JQ1

    		Epigenetic Reader Domain Reactive Oxygen Species (ROS) HIF/HIF Prolyl-Hydroxylase Cancer
    ZnPc-O3-JQ1 is a light-triggered BRD4 degrader. Under illumination, ZnPc-O3-JQ1 generates reactive oxygen species (ROS) that degrades BRD4. The degradation of BRD4 results in downregulation of HIF-1α, thereby counteracting the photodynamic therapy (PDT) resistance induced by tumor hypoxia. ZnPc-O3-JQ1 exhibits both Type I and Type II PDT mechanisms. The structure of ZnPc-O3-JQ1 consists of three parts: BRD4 ligand (HY-78695); Linker (HY-W040165); Photosensitizer (HY-176725) [1].
    ZnPc-O3-JQ1
  • HY-161769
    HL435

    		PROTACs Epigenetic Reader Domain Apoptosis Cancer
    HL435 is a heterobifunctional molecule that degrades BRD4 by linking to JQ1, with DC50 of 11.9 nM and 21.9 nM, in MDA-MB-231 and MCF-7 cells, respectively. HL435 inhibits the proliferation of MDA-MB-231, MCF-7, 22Rv1 and A549, arrests the cell cycle and induces apoptosis. HL435 exhibits antitumor activity in mouse model. (Pink: ligand for target protein JQ-1 (HY-78695); Black: linker (HY-W004640); blue: ligand for E3 ligase HL389 (HY-161770)) [1]
    HL435
  • HY-170453
    iHAC

    		Epigenetic Reader Domain Cancer
    iHAC is an inhibitor HSP90-anchoring chimera, that covalently binds BRD4 ligand (+)-JQ-1 to HSP90, and inhibits the proliferation of cancer cells. iHAC activates the anti-tumor immune response, inhibits the recurrence and metastasis of 4T1 breast cancer in mouse models [1].
    iHAC
  • HY-179589
    JQ-1 (carboxylic acid)-amine-PEG8-cyanogen

    		Target Protein Ligand-Linker Conjugates Epigenetic Reader Domain Cancer
    JQ-1 (carboxylic acid)-amine-PEG8-cyanogen is a Target Protein Ligand-Linker Conjugate that incorporates a ligand for BRD4 (HY-78695) and a PROTAC linker, which recruits E3 ligases. JQ-1 (carboxylic acid)-amine-PEG8-cyanogen can be used for the synthesis of PROTAC BET Degrader-14 (HY-179588 ) [1].
    JQ-1 (carboxylic acid)-amine-PEG8-cyanogen
  • HY-169081
    QS-57

    		PROTACs Molecular Glues Others
    QS-57 is a PROTAC targeting BRD4. QS-57 can be used as a 14-3-3 molecular glue. (Red: EN171 (HY-W1005067), black: (2-Aminoethyl) carbamic acid (HY-W398806), Blue: JQ-1 (carboxylic acid) (HY-78695)) [1].
    QS-57
  • HY-162835
    PROTAC SMARCA2/4-degrader-28

    		PROTACs Epigenetic Reader Domain Cancer
    PROTAC SMARCA2/4-degrader-28 (PROTAC 1) is a PROTAC-based partial degrader of SMARCA2 and SMARCA4(Bliue: CRL2 VHL ligand (S,R,S)-AHPC (HY-125845); Black: linker (HY-159680); Pink: a SMARCA-BD ligand (+)-JQ-1 (HY-13030)) [1].
    PROTAC SMARCA2/4-degrader-28
  • HY-175179
    LO-3-61

    		Epigenetic Reader Domain E1/E2/E3 Enzyme Cancer
    LO-3-61, a JQ-1 (HY-13030) analog bearing a truncated fumaramide handle, is a PROTAC (proteolysis-targeting chimeras)-like BRD4 degrader. LO-3-61 degrades both the long and short isoforms of BRD4 CUL4DcAr16-dependently in cells. LO-3-61 shows selectivity for BRD3 and BRD4 degradation in MDA-MB-231 cells [1].
    LO-3-61
  • HY-172562
    BTR2004

    		PROTACs Epigenetic Reader Domain Cancer
    BTR2004 is a selective BET family (BRD2/3/4) protein PROTAC degrader. BTR2004 forms a ternary complex with BRD proteins and KLHL20, inducing ubiquitination and proteasomal degradation through the UPS pathway. BTR2004 is promising for research of PC3 prostate cancer and MDA-MB-231 breast cancer cell lines. Pink: (+)-JQ1-OH (HY-161125); Blue: BTR2000 (HY-172563); Black: Linker (HY-W015236) [1] .
    BTR2004
  • HY-19541A
    I-CBP112 hydrochloride

    		Epigenetic Reader Domain Cancer
    I-CBP112 hydrochloride is a selective inhibitor of CBP/P300 that directly binds their bromodomains (Kds = 142 and 625 nM, respectively). I-CBP112 significantly reduces the leukemia-initiating potential of MLL-AF9(+) acute myeloid leukemia cells in a dose-dependent manner in vitro and in vivo. I-CBP112 increases the cytotoxic activity of BET bromodomain inhibitor JQ1 as well as doxorubicin [1].
    I-CBP112 hydrochloride
  • HY-169355
    TrimTAC1

    		PROTACs Epigenetic Reader Domain Cancer
    TrimTAC1 is a TRIM21-based PROTAC targeting BRD4. TrimTAC1 selectively degrads NUP98 FG-mEGFP-BRD4 BD2 nuclear condensates. TrimTAC1 does not degrade soluble mEGFP-BRD4 BD2 in A549 cells. (Pink: target protein ligand (+)-JQ-1 (HY-13030); Blue:E3 ligase ligand Acepromazine-OTs (HY-169356); Black: PROTAC linker (HY-W088456); E3 ligase ligand + linker: HY-169357) [1].
    TrimTAC1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: